Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Biosimilars Generic Drugs

Neuraxpharm Enters Japanese Market

Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

Strategy Japan

Teva Upbeat On Risperidone Results

Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.

Value-Added Medicines Clinical Trials

Glenmark Partners With Menarini On Ryaltris

Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.

Deals Value-Added Medicines

Richter And Mithra Extend Estelle To Latin America

Gedeon Richter and Mithra have expanded their partnership on an in-development contraceptive, Estelle, to cover several Latin American territories on top of Europe and Russia.

Deals Value-Added Medicines

Apotex Loses Again On Alternate Salt Alimta In US

Apotex’ 505(b)(2) new drug application rival to Alimta will stay off the US market after the Federal Circuit found that a lower court had correctly concluded that prosecution history estoppel did not bar Lilly’s infringement claims against the Canadian firm under the doctrine of equivalents.

Intellectual Property Legal Issues
See All
UsernamePublicRestriction

Register